Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial

The British Journal of Dermatology
B FarkasG Fekete

Abstract

Diabetes mellitus (DM) affects an estimated 175 million people world-wide. Approximately one-third of patients with DM have toenail onychomycosis. To determine the efficacy and safety of terbinafine treatment of toenail onychomycosis in patients with DM receiving insulin and/or oral antidiabetic agents. Special interest was focused on potential drug interactions with oral hypoglycaemic substances. In a multicentre trial, patients suffering from insulin-dependent DM (IDDM) or non- insulin-dependent DM (NIDDM) with toenail onychomycosis were treated for 12 weeks with oral terbinafine 250 mg daily and followed up to 48 weeks. In addition to clinical, mycological and laboratory investigations, blood glucose levels were monitored. At the end of the trial (week 48), a mycological cure rate of 73% was achieved. The rates of clinical cure and complete cure (mycological cure plus clinical cure) were 57% and 48%, respectively. There was no statistically significant difference between the NIDDM and IDDM groups with respect to the cure rates (P > 0.05). No hypoglycaemic episode was reported and none of the patients had hypoglycaemia during the treatment phase. With excellent cure rates and a good tolerability profile, terbinafine should co...Continue Reading

References

Sep 1, 1996·Journal of the American Academy of Dermatology·P Rich
Jan 13, 1998·Journal of the American Podiatric Medical Association·L A Levy
May 22, 1998·Journal of the American Academy of Dermatology·H I Katz
Jan 20, 1999·The British Journal of Dermatology·A K GuptaR C Summerbell
Jun 15, 1999·Journal of the American Academy of Dermatology·R K Scher
Jul 30, 1999·Journal of the American Academy of Dermatology·A K GuptaN H Shear
Oct 6, 1999·Journal of the European Academy of Dermatology and Venereology : JEADV·E Haneke
Apr 14, 2000·BMJ : British Medical Journal·R Dobson

❮ Previous
Next ❯

Citations

Dec 6, 2011·Journal of Foot and Ankle Research·Lisa MatriccianiSara Jones
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Jason G Newland, Susan M Abdel-Rahman
Feb 13, 2004·Drugs & Aging·James S Tan, Warren S Joseph
Jun 6, 2009·American Journal of Clinical Dermatology·Peter MayserDebby Budihardja
Dec 20, 2013·American Journal of Clinical Dermatology·Daniel Coelho de SáAntonella Tosti
Aug 24, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·M-H Schmid-Wendtner, H C Korting
Oct 26, 2006·Journal of the European Academy of Dermatology and Venereology : JEADV·A K GuptaC W Lynde
Jun 19, 2015·Indian Journal of Dermatology, Venereology and Leprology·Pravesh YadavShukla Das
Nov 21, 2014·The British Journal of Dermatology·M AmeenM Richardson
Mar 17, 2015·Journal of Cutaneous Medicine and Surgery·Aditya K Gupta, Maryse Paquet
Mar 25, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·S CathcartB e Elewski
Jan 18, 2006·Journal of the American Podiatric Medical Association·Erin M Warshaw
Jul 24, 2008·Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry·Andrei BaraschGregg H Gilbert
Dec 13, 2002·American Journal of Clinical Dermatology·Malcolm J M DarkesKaren L Goa
Jul 1, 2018·Journal of the American Academy of Dermatology·Shari R Lipner, Richard K Scher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.